Tamás Pintér - Concepedia

Author

Tamás Pintér

Petz Aladár Megyei Oktató Kórház ORCID

Also Known As

T Pinter, T Pintér, T. Pinter, T. Pintér, Tamas Pinter, Tamàs Pintér, Tamás Pinter, Tamás Pintér, Tomas Pinter

Publications

13.4K

Citations

H-Index

Concepts

All Affiliations

Petz Aladár Megyei Oktató Kórház Cancer Trials Ireland University of California, Los Angeles Szent János Kórház Johannes Gutenberg University Mainz

About

Tamás Pintér is an author at Petz Aladár Megyei Oktató Kórház specializing in oncology, cancer therapeutics, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	18	3.5K
2	Health Sciences	3	3	227
3	Obstetrics	3	3	79
4	Immunology	2	2	160
5	Cell Biology	1	1	128

Tamás Pintér

Publications

13.3K

Citations

H-Index

Page 1

	Year	Citations
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre, New England Journal of Medicine	2009	3.8K
Adjuvant Trastuzumab in HER2-Positive Breast Cancer Dennis J. Slamon, W. Eiermann, Nicholas J. Robert, New England Journal of Medicine	2011	2.7K
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study Richard S. Finn, John Crown, István Láng, The Lancet Oncology Cyclin-dependent Kinase 4/6Breast OncologyInhibitor PalbociclibMedicinePharmacology	2014	1.9K
Adjuvant Docetaxel for Node-Positive Breast Cancer Miguel Martín, Tadeusz Pieńkowski, John R. Mackey, New England Journal of Medicine	2005	950
Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer Stephen Chan, Kay Friedrichs, D. Noel, Journal of Clinical Oncology	1999	638
Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study. DJ Slamon, W. Eiermann, Nicholas J. Robert, Cancer Research Breast OncologyOncologyCyclophosphamide FollowedBreast Cancer PatientsCancer Management	2009	554
Docetaxel and Doxorubicin Compared With Doxorubicin and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer: Results of a Randomized, Multicenter, Phase III Trial Jean-Marc Nabholtz, Carla I. Falkson, J. Szántó, Journal of Clinical Oncology	2003	383
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial John R. Mackey, Miguel Martín, Tadeusz Pieńkowski, The Lancet Oncology Node-positive Breast CancerBreast OncologyOncologyAdjuvant DocetaxelBcirg 001	2012	221
Darbepoetin Alfa for the Treatment of Anemia in Patients With Active Cancer Not Receiving Chemotherapy or Radiotherapy: Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Robert E. Smith, Matti Aapro, Heinz Ludwig, Journal of Clinical Oncology	2008	212
Randomized, Multicenter, Controlled Trial Comparing the Efficacy and Safety of Darbepoetin Alfa Administered Every 3 Weeks With or Without Intravenous Iron in Patients With Chemotherapy-Induced Anemia Laurent Bastit, A. Vandebroek, Sevilay Altıntaş, Journal of Clinical Oncology	2008	194

Page 1